BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of “Moderate Buy” by Analysts

BeiGene, Ltd. (NASDAQ:BGNEGet Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $261.40.

A number of analysts have issued reports on BGNE shares. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $185.00 price target on shares of BeiGene in a report on Tuesday, February 6th. Citigroup reduced their price target on shares of BeiGene from $290.00 to $285.00 and set a “buy” rating on the stock in a report on Thursday, October 26th. Finally, StockNews.com upgraded shares of BeiGene from a “sell” rating to a “hold” rating in a report on Thursday, November 9th.

Check Out Our Latest Stock Analysis on BeiGene

BeiGene Trading Up 2.9 %

Shares of BeiGene stock opened at $146.98 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.16 and a quick ratio of 2.91. The stock has a market capitalization of $14.02 billion, a PE ratio of -15.87 and a beta of 0.60. The company’s fifty day simple moving average is $169.92 and its 200-day simple moving average is $183.52. BeiGene has a 1-year low of $132.95 and a 1-year high of $272.49.

BeiGene (NASDAQ:BGNEGet Free Report) last announced its quarterly earnings results on Thursday, November 9th. The company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.38) by $5.39. The company had revenue of $781.30 million for the quarter, compared to the consensus estimate of $596.75 million. BeiGene had a negative net margin of 43.53% and a negative return on equity of 23.83%. BeiGene’s revenue for the quarter was up 101.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($5.39) EPS. As a group, equities analysts anticipate that BeiGene will post -7.48 earnings per share for the current year.

Hedge Funds Weigh In On BeiGene

Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in BeiGene during the 2nd quarter valued at about $40,000. PNC Financial Services Group Inc. grew its holdings in BeiGene by 26.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock valued at $54,000 after purchasing an additional 51 shares during the last quarter. Toronto Dominion Bank grew its holdings in BeiGene by 166.4% during the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock valued at $60,000 after purchasing an additional 208 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its holdings in BeiGene by 20.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after purchasing an additional 76 shares during the last quarter. Finally, Exchange Traded Concepts LLC bought a new position in BeiGene during the 2nd quarter valued at about $90,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

(Get Free Report

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Stories

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.